A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Hemab ApS
Study ID
NCT06610201
Status
Recruiting
Apply to this trial

Conditions

  • Von Willebrand Disease (VWD)
  • Von Willebrand Disease (VWD), Type 1
  • Von Willebrand Disease (VWD), Type 2
  • Von Willebrand Disease (VWD), Type 3
  • Von Willebrand Disease, Type 2A
  • Von Willebrand Disease, Type 2M
  • Von Willebrand Disease, Type 2N

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clinical outcomes of patients with VWD, Type 1 — OTHER
    Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1
  • Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 — OTHER
    Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2A, Type 2M, Type 2N and Type 3.

Study Details

The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)

Key Dates

Start date
Aug 30, 2024
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: VWD Type 1 (residual VWF antigen and/or activity less than 30 IU per dL)
  • Arm: VWD Type 2A, Type 2M, Type 2N, or Type 3

Primary Outcome Measure

Annualized bleeding event rate [ Time Frame: 4.5 to 12.5 months ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
Phoenix Children's HospitalPhoenixArizona85016
Taylor Janiec
[email protected]
602-933-0091
Arkansas Children's HospitalLittle RockArkansas72202-3591
Maggie McDuffie
[email protected]
501-364-5436
Children's Hospital of Los AngelesLos AngelesCalifornia90027
Sibgha Zaheer
[email protected]
323-361-4908
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer CenterMiamiFlorida33136
Fernando Corrales-Medina
[email protected]
305-243-8652
Emory Children's CenterAtlantaGeorgia30329
Gabrille Dean
[email protected]
404-785-3153
Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis CenterIndianapolisIndiana46260
Sanjay Ahuja
[email protected]
317-871-0000
Tulane University School of MedicineNew OrleansLouisiana70112-2699
Melody S. Benton
[email protected]
504-988-3596
University of Michigan Hospitals, Department of Hemophilia and Coagulation DisordersAnn ArborMichigan48109
Angela Weyand
[email protected]
734-764-9336
Mayo Clinic - RochesterRochesterMinnesota55905
Rajiv Pruthi
[email protected]
507-266-1944
Oregon Health & Science UniversityPortlandOregon97239-3098
Kristina Haley
[email protected]
503-494-8716
Hemophilia Center of Western PennsylvaniaPittsburghPennsylvania15213
Nicoletta Manchin
[email protected]
412-209-7280
The University of Texas Southwestern Medical CenterDallasTexas75390
Yu-Min Shen
[email protected]
214-648-1929
Washington Institute For Coagulation (WIC)SeattleWashington98101
Abigail deLa Cruz
[email protected]
206-821-2594

Find similar trials in Phoenix, AZ

By research site
Phoenix Children's Hospital· Phoenix, AZArkansas Children's Hospital· Little Rock, ARChildren's Hospital of Los Angeles· Los Angeles, CAUniversity of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center· Miami, FLEmory Children's Center· Atlanta, GAInnovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center· Indianapolis, IN

Related Studies